Parkinson disease

被引:682
|
作者
Balestrino, R. [1 ]
Schapira, A. H., V [2 ]
机构
[1] Univ Turin, Dept Neurosci, Turin, Italy
[2] UCL, Dept Clin & Movement Neurosci, Queen Sq Inst Neurol, UCL Royal Free Campus,Rowland Hill St, London NW3 2PF, England
关键词
clinical; genetics; movement disorders; neurodegeneration; Parkinson disease; pathophysiology; treatment; LEVODOPA-INDUCED DYSKINESIA; NURSING-HOME PLACEMENT; QUALITY-OF-LIFE; ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; LEWY BODY; ATYPICAL PARKINSONISM; DIAGNOSTIC-CRITERIA; MOTOR FLUCTUATIONS; NONMOTOR SYMPTOMS;
D O I
10.1111/ene.14108
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108-257/100 000 and 11-19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%-15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non-motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded alpha -synuclein, which is found in intra-cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist.
引用
收藏
页码:27 / 42
页数:16
相关论文
共 50 条
  • [21] PARKINSON DISEASE
    不详
    BMJ-BRITISH MEDICAL JOURNAL, 1948, 1 (4561): : 1119 - 1120
  • [23] ON PARKINSON DISEASE
    SCHWAB, RS
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1959, 84 (34) : 1485 - 1489
  • [24] The Parkinson disease before James Parkinson
    Francesco Raudino
    Neurological Sciences, 2012, 33 : 945 - 948
  • [25] The Parkinson disease before James Parkinson
    Raudino, Francesco
    NEUROLOGICAL SCIENCES, 2012, 33 (04) : 945 - 948
  • [26] PARKINSON DISEASE Progress towards a molecular biomarker for Parkinson disease
    Foulds, Penelope
    Mann, David M. A.
    Mitchell, J. Douglas
    Allsop, David
    NATURE REVIEWS NEUROLOGY, 2010, 6 (07) : 359 - 361
  • [27] PARKINSON DISEASE Another player in gene therapy for Parkinson disease
    Kaplitt, Michael G.
    NATURE REVIEWS NEUROLOGY, 2010, 6 (01) : 7 - 8
  • [28] PARKINSON DISEASE How reliable are prodromal indicators of Parkinson disease?
    Silveira-Moriyama, Laura
    Lees, Andrew J.
    NATURE REVIEWS NEUROLOGY, 2015, 11 (01) : 5 - U6666
  • [29] PARKINSON DISEASE Could a prostate drug be repurposed for Parkinson disease?
    Wood, Heather
    NATURE REVIEWS NEUROLOGY, 2019, 15 (11) : 621 - 621
  • [30] Parkinson's Disease 2 The pathogenesis of Parkinson's disease
    Morris, Huw R.
    Spillantini, Maria Grazia
    Sue, Carolyn M.
    Williams-Gray, Caroline H.
    LANCET, 2024, 403 (10423): : 293 - 304